The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism.
Abstract
Angiotensin II, when given in low doses, raises blood pressure slowly. When tested in vitro on vascular smooth muscle cells, it has mitogenic and trophic effects; it is not known if it has these effects in vivo. Our purpose was to determine whether vascular hypertrophy develops during slow pressor infusion of angiotensin II and, if so, whether it is pressure induced. Three experiments were done in rats infused subcutaneously with angiotensin II (200 ng/kg/min) by minipump for 10-12 days. Experiment 1: Angiotensin II gradually raised systolic blood pressure (measured in the tail) from 143 +/- 2 to 208 +/- 8 mm Hg (mean +/- SEM), significantly suppressing plasma renin and increasing threefold (NS) plasma angiotensin II. There was no loss of peptide in the pump infusate when tested at the end of the experiment. Experiment 2: In the perfused mesenteric circulation, vasoconstrictor responses to norepinephrine, vasopressin, and KCl were enhanced in rats given a slow pressor infusion of angiotensin II, but sensitivity of responses was not altered. This combination of changes suggests that vascular hypertrophy develops during slow pressor infusion of angiotensin II. Experiment 3: Vessel myography was done after angiotensin II infusion with and without a pressor response. Angiotensin II raised systolic blood pressure, increased heart weight, and produced myographic changes of vascular hypertrophy in the mesenteric circulation, increasing media width, media cross-sectional area, and media/lumen ratio. Hydralazine given with angiotensin II prevented the rise of pressure and the cardiac effect but not the vascular changes. Two-way analysis of variance showed that angiotensin II significantly increased media width, media cross-sectional area, and media/lumen ratio, all independent of hydralazine. Thus, although hydralazine inhibits the pressor and cardiac effects of angiotensin II, suggesting a pressor mechanism for the cardiac change, it does not inhibit structural vascular change, which suggests that at least part of the effect has a non-pressor mechanism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mulvany, M. J., & Halpern, W. (1977) · Circulation Research · doi:10.1161/01.res.41.1.19 · Cited by 2,140
Self-citationAngiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells.
Geisterfer, A. A., Peach, M. J., & Owens, G. K. (1988) · Circulation Research · doi:10.1161/01.res.62.4.749 · Cited by 1,065
McGregor, D. D. (1965) · The Journal of Physiology · doi:10.1113/jphysiol.1965.sp007572 · Cited by 639
Naftilan, A. J., Pratt, R. E., & Dzau, V. J. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114032 · Cited by 623
Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells.
Berk, B. C., Vekshtein, V, Gordon, H. M., & Tsuda, T. (1989) · Hypertension · doi:10.1161/01.hyp.13.4.305 · Cited by 556
Mulvany, M. J., Hansen, O. K., & Aalkjaer, C. (1978) · Circulation Research · doi:10.1161/01.res.43.6.854 · Cited by 460
Self-citationPhenotype-dependent response of cultured aortic smooth muscle to serum mitogens.
Chamley-Campbell, J. H., Campbell, G. R., & Ross, R. (1981) · The Journal of cell biology · doi:10.1083/jcb.89.2.379 · Cited by 444
Folkow, B. (1978) · Clinical Science · doi:10.1042/cs055003s · Cited by 403 · cited 1×
“Increased thickness of the smooth muscle layer of resistance vessels, which is common in hypertension, may be a consequence and a contributory cause of increased arterial pressure.(1)-(2) According to Folkow(1) and Korner and his colleagues(3), the two processes interact as a vascular amplifier raising arterial pressu…”
BackgroundNeovascularization produced by angiotensin II.
Fernandez, L. A., Twickler, J., & Mead, A. (1985) · PubMed · Cited by 389
Harrap, S. B., van der Merwe, W. M., Griffin, S. A., MacPherson, F., & Lever, A. F. (1990) · Hypertension · doi:10.1161/01.hyp.16.6.603 · Cited by 339
Self-citation"Structural factor" in primary and secondary hypertension.
Folkow, B. (1990) · Hypertension · doi:10.1161/01.hyp.16.1.89 · Cited by 336
Effects of angiotensin II and vasopressin on human smooth muscle cells in vitro
Campbell-Boswell, M., & Robertson, A. L. (1981) · Experimental and Molecular Pathology · doi:10.1016/0014-4800(81)90066-6 · Cited by 305
Adrenergic Facilitation by Angiotensin: Does it Serve a Physiological Function?
Zimmerman, B. G. (1981) · Clinical Science · doi:10.1042/cs0600343 · Cited by 255
Interaction Between Sympathetic and Renin-angiotensin System
Zimmerman, B. G., Sybertz, E. J., & Wong, P. C. (1984) · Journal of Hypertension · doi:10.1097/00004872-198412000-00002 · Cited by 244
Slow Pressor Mechanisms in Hypertension: A Role for Hypertrophy of Resistance Vessels?
Lever, A. F. (1986) · Journal of Hypertension · doi:10.1097/00004872-198610000-00001 · Cited by 243
Self-citationOwens, G. K. (1987) · Hypertension · doi:10.1161/01.hyp.9.2.178 · Cited by 227
Area postrema is critical for angiotensin-induced hypertension in rats.
Fink, G. D., Bruner, C. A., & Mangiapane, M. L. (1987) · Hypertension · doi:10.1161/01.hyp.9.4.355 · Cited by 173
Captopril reduces aortic and microvascular growth in hypertensive and normotensive rats.
Wang, D. H., & Prewitt, R. L. (1990) · Hypertension · doi:10.1161/01.hyp.15.1.68 · Cited by 164
Trophic effects of peripheral adrenergic nerves on vascular structure.
Bevan, R. D. (1984) · Hypertension · doi:10.1161/01.hyp.6.6_pt_2.iii19 · Cited by 161
Mulvany, M. J., Aalkjær, C., & Christensen, J. (1980) · Hypertension · doi:10.1161/01.hyp.2.5.664 · Cited by 138
Self-citationA micro assay for active and total renin concentration in human plasma based on antibody trapping
Millar, J. A., LECKIE, B. J., Morton, J. J., Jordan, J., & Tree, M. (1980) · Clinica Chimica Acta · doi:10.1016/0009-8981(80)90050-9 · Cited by 137
Dickinson, C. J., & Lawrence, J. R. (1963) · The Lancet · doi:10.1016/s0140-6736(63)91929-9 · Cited by 136
Measurement of plasma angiotensin II
Morton, J. J., & Webb, D. J. (1985) · Clinical Science · doi:10.1042/cs0680483 · Cited by 109
Comparison of fast and slow pressor effects of angiotensin II in the conscious rat
Brown, A. J., CASALS‐STENZEL, J., Gofford, S., Lever, A. F., & Morton, J. J. (1981) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1981.241.3.h381 · Cited by 95
Self-citationWright, C. E., Angus, J. A., & Korner, P. I. (1987) · Hypertension · doi:10.1161/01.hyp.9.2.122 · Cited by 87
Morton, J. J., & Wallace, E. C. H. (1983) · Clinical Science · doi:10.1042/cs0640359 · Cited by 78
Cellular hypertrophy in mesenteric resistance vessels from renal hypertensive rats.
Korsgaard, N., & Mulvany, M. J. (1988) · Hypertension · doi:10.1161/01.hyp.12.2.162 · Cited by 76
Self-citationPrimary versus secondary structural changes of the blood vessels in hypertension
Lee, R. M. K. W., & Smeda, J. S. (1985) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y85-070 · Cited by 72
Chronic angiotensin II infusion decreases renal norepinephrine overflow in conscious dogs.
Carroll, R. G., Lohmeier, T. E., & Brown, A. J. (1984) · Hypertension · doi:10.1161/01.hyp.6.5.675 · Cited by 71
Bean, B. L., Brown, J. J., CASALS‐STENZEL, J., Fräser, R., Lever, A. F., Millar, J. A., Morton, J. J., Petch, B., Riegger, A. J. G., Robertson, J. I. S., et al. (1979) · Circulation Research · doi:10.1161/01.res.44.4.452 · Cited by 67
Self-citationCausal and Homoeostatic Factors in Hypertension
Korner, P. (1982) · Clinical Science · doi:10.1042/cs063005s · Cited by 61
Lyall, F., Morton, J. J., Lever, A. F., & Cragoe, E. J. (1988) · Journal of Hypertension · doi:10.1097/00004872-198812040-00138 · Cited by 54
Self-citationJespersen, L. T., Nyborg, N. C. B., Pedersen, O. L., Mikkelsen, E. O., & Mulvany, M. J. (1985) · Hypertension · doi:10.1161/01.hyp.7.5.734 · Cited by 48
Self-citationEnhanced slow-pressor response to angiotensin II in spontaneously hypertensive rats.
Li, P., & Jackson, E. K. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21097-7 · Cited by 48
Huelsemann, J. L., Sterzel, R. B., McKenzie, D. E., & Wilcox, C. S. (1985) · Hypertension · doi:10.1161/01.hyp.7.3.374 · Cited by 38
Scott‐Burden, T., Resink, T. J., Bürgin, M., & Bühler, F. R. (1989) · Journal of Cellular Physiology · doi:10.1002/jcp.1041410206 · Cited by 35
Increased aortic DNA synthesis precedes renal hypertension in rats. An obligatory step?
Loeb, A. L., Mandel, H. G., Straw, J. A., et al. (1986) · Hypertension · doi:10.1161/01.hyp.8.9.754 · Cited by 31
Subpressor angiotensin II infusions do not stimulate sympathetic activity in humans
Goldsmith, S. R., & Hasking, G. J. (1990) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.1990.258.1.h179 · Cited by 16
Ohnishi, A., Li, P., Branch, R. A., Holycross, B. J., & Jackson, E. K. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113038 · Cited by 14
Schlegel, P. A., Monney, M., & Brunner, H. R. (1985) · Clinical and Experimental Hypertension · doi:10.3109/10641968509073611 · Cited by 13
Cited by
International Union of Pharmacology. XXIII. The Angiotensin II Receptors
de Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W., & Unger, T. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01458-3 · Cited by 2,132
Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases
Kim, S., & Iwao, H. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01434-0 · Cited by 983
Small artery structure in hypertension. Dual processes of remodeling and growth.
Heagerty, A. M., Aalkjaer, C., Bund, S. J., Korsgaard, N., & Mulvany, M. J. (1993) · Hypertension · doi:10.1161/01.hyp.21.4.391 · Cited by 645
Self-citationAngiotensin Receptors and Their Antagonists
Goodfriend, T. L., Elliott, M. E., & Catt, K. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606203342507 · Cited by 558
Xiao, L., & Harrison, D. G. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.01.013 · Cited by 545
Metadata
- Authors
- Griffin, S. A., Brown, W. C., MacPherson, F., McGrath, J. C., Wilson, V. G., Korsgaard, N., Mulvany, M. J., & Lever, A. F.
- Venue
- Hypertension
- Published
- 1991-05
- Volume
- 17
- Issue
- 5
- Pages
- 626-635
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2142961055
- Cited by
- 391
- References
- 40
- FWCI
- 14.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.